Bruce Power announces milestone in medical Lu-177 production

June 24, 2022, 12:01PMNuclear News
The new IPS installed in Bruce Power’s Unit 7 will produce Lu-177 for treating cancer. (Photo: Bruce Power)

An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.

To continue reading, log in or create a free account!

Related Articles

Flamanville-3 reaches full power

December 17, 2025, 3:03PMNuclear News

France’s state-owned electric utility EDF has announced that Flamanville-3—the country’s first EPR—reached full nuclear thermal power for the first time, generating 1,669 megawatts of...

Constellation appoints new nuclear chief

September 5, 2025, 7:01AMNuclear News

Longtime nuclear industry executive Chris Mudrick has been named the new chief nuclear officer at Constellation Energy, effective September 29. He will take over the position from Dave...